Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer’s rating is based on several factors that highlight the potential of RegenXBio’s RGX-202 program. Despite the recent concerns regarding safety in a related therapy, Frommer remains optimistic about RGX-202 due to its evolving risk/benefit profile, particularly in the context of its next-generation microdystrophin construct. The company’s ongoing Phase 3 AFFINITY DUCHENNE study, which focuses on ambulatory patients, is progressing well, with more than half of the enrollment completed.
Furthermore, RegenXBio’s proactive approach to immune suppression, which includes the use of sirolimus and other inhibitors, is seen as a positive step in mitigating potential safety issues. The anticipation of topline data from the pivotal study in the first half of 2026, which could support a BLA submission for accelerated approval, adds to the confidence in the company’s strategic direction. These factors collectively contribute to Frommer’s Buy rating for RegenXBio, reflecting a belief in the company’s ability to navigate current challenges and capitalize on its therapeutic advancements.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $22.00 price target.
RGNX’s price has also changed slightly for the past six months – from $8.540 to $9.160, which is a 7.26% increase.